Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7798204 | 0.76 | HSD11B1 (0.44) | KDM4EALDH1A1HPGD | |
| SCHEMBL9684691 | 0.67 | KDM4E (0.65) | KDM4EALDH1A1HPGDGLO1KMT2A | |
| SCHEMBL6924466 | 0.67 | CA1 (0.55) | KDM4EALDH1A1HPGDKMT2ACA1 | |
| SCHEMBL4064446 | 0.65 | NPSR1 (0.54) | KDM4EALDH1A1HPGDKMT2A | |
| Sulfuric Acid SCHEMBL15238309 | 0.65 | MAPT (0.52) | KDM4EALDH1A1KMT2ACA1CA2 | |
| SCHEMBL1387746 | 0.65 | CA1 (0.57) | KDM4EALDH1A1HPGDGLO1KMT2A | |
| SCHEMBL633995 | 0.64 | KMT2A (0.76) | KDM4EALDH1A1HPGDKMT2ACA1 | |
| SCHEMBL5712482 | 0.64 | SMN1; SMN2 (0.41) | KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL7799450 | 0.64 | NOS2 (0.43) | — | |
| SCHEMBL11759715 | 0.64 | CA1 (0.45) | ALDH1A1KMT2ACA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | KDM4E 4737/4885ALDH1A1 2598/4885HPGD 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.